Related Experiment Video
Updated: Jun 14, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Dabigatran etexilate: a new thrombin inhibitor
1Gosford District Hospital, Gosford, NSW, Australia. averma@medemail.com.au
The Medical Journal of Australia
|April 7, 2010
Summary
Dabigatran etexilate shows comparable efficacy and safety to enoxaparin for preventing venous thromboembolism in orthopedic surgery patients. This oral direct thrombin inhibitor may offer a viable alternative to enoxaparin.
Area of Science:
- Pharmacology
- Thromboprophylaxis
- Orthopedic Surgery
Background:
- Dabigatran etexilate, an oral prodrug of dabigatran, is approved for thromboprophylaxis in adults undergoing hip or knee replacement.
- Dabigatran is a direct thrombin inhibitor with predictable pharmacokinetics, potentially replacing enoxaparin in certain clinical settings.
Purpose of the Study:
- To evaluate the efficacy and safety of dabigatran etexilate compared to enoxaparin for thromboprophylaxis in orthopedic surgery.
Main Methods:
- Pooled efficacy and safety data from large-scale phase III clinical trials were analyzed.
- Comparison of venous thromboembolism and major bleeding rates between dabigatran etexilate and enoxaparin groups.
Main Results:
- Dabigatran etexilate demonstrated non-inferiority to enoxaparin for total venous thromboembolism.
- Pooled safety results showed similar major bleeding rates between dabigatran etexilate and enoxaparin.
- Dabigatran did not show non-inferiority compared to enoxaparin 30 mg twice daily.
Conclusions:
- Dabigatran etexilate presents a viable oral alternative to enoxaparin for thromboprophylaxis in orthopedic surgery due to its efficacy, safety, and pharmacokinetic profile.
- Considerations include the lack of an antidote, limited use in renal disease, and potential drug interactions.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...